Navigation Links
Napo Presents at ISPOR Meeting in Toronto
Date:5/12/2008

SOUTH SAN FRANCISCO, Calif., May 12 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented a poster in collaboration with QualityMetric, Inc. describing the development of a patient reported outcomes questionnaire focused on the Health-Related Quality of Life (HR-QoL) aspects of chronic diarrhea in persons living with HIV/AIDS at the 13th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Toronto, Ontario, May 3 through 7, 2008.

Using classic and modern psychometric methods, a single scale comprised of 9 survey questions covering two HR-QoL content areas was developed. The survey questions showed consistency across gender, race and education level, demonstrated a statistically significant greater negative impact on HR-QoL with more frequent and more severe diarrhea symptoms.

Cathy Olufs, President, AIDS Activist Treatment Coalition (ATAC) stated, "We are fortunate to currently have a wide choice of HIV medications and combinations. This makes understanding medication side effects and their impact on a patient's quality of life more important than ever. Controlling side effects such as diarrhea can help give patients access to the full armamentarium of anti-retroviral drugs. We are pleased to see Napo taking the initiative to develop this new instrument to measure health-related quality of life as affected by diarrhea."

For more information please contract:

Napo Pharmaceuticals, Inc.

Lisa Conte, Chief Executive Officer

1 + 650 616 1902

David Golman, Pharm.D., Senior Director, Clinical Operations

1+ 760 918 5718

About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program:

CRO-HIV for AIDS diarrhea, Phase 3

CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2

CRO-ID for acute infectious diarrhea (including cholera), Phase 2

CRO-PED for pediatric diarrhea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection.

Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China.

For more information please visit http://www.napopharma.com.

About ISPOR

ISPOR promotes the science of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical outcomes, economic outcomes, and patient-reported outcomes) and facilitates the translation of this research into useful information for healthcare decision-makers to ensure that society allocates scarce health care resources wisely, fairly and efficiently.


'/>"/>
SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Mich. , May 31, 2016  Diplomat Pharmacy, Inc. ... pharmacy, has announced that Phil Hagerman , Chairman & ... the upcoming William Blair 36 th Annual Growth Stock ... Mr. Hagerman and Mr. Whelan are scheduled to present at ... Central Time. A live audio-only webcast of the presentation and ...
(Date:5/31/2016)... , May 31, 2016 ... ingredient in food, cosmetics and pharmaceuticals, with global volume ... worth US$ 1.6 Bn. Demand for aloe ... juices, and yogurts will continue its upward momentum in ... will also boost positive sentiment on aloe vera, with ...
(Date:5/31/2016)... , Isansys  Lifecare, a new generation digital healthcare ... wireless patient monitoring platform, as it ships more systems to hospitals ... Scotland and Norway ... launched earlier this year, is now being used in ground-breaking ... new technology significantly enhances the user experience and provides ...
Breaking Medicine Technology:
(Date:5/31/2016)... CA (PRWEB) , ... May ... ... approach to healthcare that considers individuals’ genetic characteristics and the physical and ... precision therapy work in sync. In personalized medicine, diagnosing an individual’s disease ...
(Date:5/31/2016)... ... 2016 , ... More than 80 representatives of the Hepatitis B Foundation ... Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City Hall ... leading cause of liver cancer. , Foundation leaders and the citywide coalition they created, ...
(Date:5/31/2016)... San Jose, CA (PRWEB) , ... May 31, 2016 , ... ... collaboration , announces its strategic partnership with e-Jan Networks Co., the leading provider ... Japan enterprises are customers of e-Jan Networks’s leading CACHATTO remote access solution. ...
(Date:5/31/2016)... ... ... years ago it was revolutionary: enabling the people who hear distressing voices to speak ... approach has proven transformative, both for people who hear voices and for the field ... around the world, but it still lags in the United States. , Now, Gail ...
(Date:5/31/2016)... Fort Walton Beach, Florida (PRWEB) , ... May ... ... weather-forecasting technology to Jay Butch of CertainTeed Corporation, he knew it was something ... technology is as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director ...
Breaking Medicine News(10 mins):